EuroPCR 2014 session defines future horizons for renal denervation

During EuroPCR 2014, Felix Mahfoud, University Hospital in Homburg, Germany, and Konstantinos Tsioufis, University of Athens, Greece, reflected on the potential future role of modulation of the sympathetic nervous system in patients with difficult-to-control hypertension.

In the context of the SYMPLICITY-HTN-3 clinical trial results, questions were raised about the extent of the procedure's efficacy although the randomised, controlled trial confirmed the safety of .

"In terms of efficacy, some studies have shown that renal denervation can achieve a clinically relevant reduction of office and ambulatory blood pressure in with difficult-to-control hypertension. There is a need for more research to identify the pathophysiology of the condition and to select the best patients who will benefit from treatment with the procedure," Tsioufis stated.

F. Mahfoud expanded on this, saying that the safety of renal denervation has never been contested as the primary safety endpoint of the study was met. F. Mahfoud said that, although renal denervation with radiofrequency did not show a significant difference with regard to the efficacy endpoint compared to the control group, it is unlikely that the procedure does not work in humans.

Other aspects to be considered are: SYMPLICITY HTN-3 may be underpowered; antihypertensive drugs may have been maximised, but not stabilised; the patient population may differ from Caucasians recruited in previous trials; the results may just be accidental; and the procedure may not have been performed effectively.

The underlying pathophysiology is much more complex than initially thought: "Maybe we are moving away from Symplicity to complexity, in terms of how we deliver energy and where the sweet spots for renal denervation are," F. Mahfoud commented. "On top of it there may be a learning curve for renal denervation; there is a lot more to learn and a lot more to understand," concluded F. Mahfoud.

"Renal denervation was developed as a promising therapy for the treatment of patients who suffer from resistant hypertension lacking treatment alternatives," stated William Wijns, EuroPCR Course Co-director. The physicians all agreed that this condition represents an unmet clinical need, adding that up until now, data from clinical trials and registries confirmed that renal denervation is a safe procedure. Further to this, they said that renal denervation is an option in patients with difficult-to-control hypertension, in whom other treatments have failed.

More information: Further information on press registration may be found at www.europcr.com/page/press/393-press.html

add to favorites email to friend print save as pdf

Related Stories

Renal denervation shows no benefit in resistant hypertension

Mar 31, 2014

Renal denervation fell short of primary and secondary efficacy goals in patients with severe resistant hypertension but did meet the primary safety endpoints, according to keenly awaited data from SYMPLICITY HTN-3 presented ...

ESC recommends patients and centres for renal denervation

Apr 25, 2013

Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation ...

Recommended for you

Ebola vaccine promising in first human trials

8 hours ago

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

11 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

EU calls for 5,000 doctors to fight Ebola

12 hours ago

The European Commission called for 5,000 doctors to be sent from EU states to combat west Africa's Ebola epidemic, a European source with knowledge of the matter said on Wednesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.